Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Respiratory Prescribing in Tower Hamlets Bill Sandhu Head of Medicines Management, Tower Hamlets Medicines Management Team Prescribing Expenditure April-November 13-14 • • • Cost of Inhalers for all indications is £2.6 Million This is 9% of the total budget for prescribing We are spending around £280K a quarter on fluticasone alone Change in Prescribing Spend Versus Prevalence Background – Uncontrolled Asthma is a European Issue • • • • Patients with controlled asthma Comprises 51% of ICS users across Europe1 Fewer symptoms and less need for SABAs than patients with uncontrolled asthma2 No emergency visits2 Ability to take part in everyday activities2 • • • • • • ICS = inhaled corticosteroids SABA = short-acting β2-agonists Patients with uncontrolled asthma Comprises 49% of ICS users across Europe1 Asthma attacks3 Increased symptoms versus patients with controlled asthma3 Sleep disturbances3 Unscheduled healthcare visits: hospitalisations; GP visits3 Major limitations on activities3 1. Cazzoletti L, et al. J Allergy Clin Immunol 2007;120:1360–7 2. Bateman ED, et al. Eur Respir J 2008;31:143–78 3. Rabe K, et al. Eur Respir J 2000;16: 802–7 Mortality rates for asthma in adults in the UK and Europe Mortality due to asthma in Europe (per 100,000 population)1 <2 2–4 4–8 >8 UK Spain Ireland Finland The Netherlands Greece Slovakia Czech Republic Ukraine Slovenia France Denmark Sweden Austria Lithuania Poland Germany Belgium Russia Portugal In the UK: • >1,143 deaths from asthma in 2010 • On average three people die from asthma/day • 90% of these are preventable2 1. Loddenkemper R, ed. European Lung White Book. Part 2, Major Respiratory Diseases, 2003 2. Asthma UK. http://www.asthma.org.uk/asthma-facts-and-statistics; accessed May 2013 What’s the Issue? Cost per Prescription Symbicort_Turbohaler 400mcg/12mcg (60 D) Symbicort_Turbohaler 200mcg/6mcg (120 D) Symbicort_Turbohaler 100mcg/6mcg (120 D) Seretide 500_Accuhaler 500mcg/50mcg(60D) Seretide 50_Evohaler 50mcg/25mcg (120 D) Seretide 250_Evohaler 250mcg/25mcg(120D) Seretide 250_Accuhaler 250mcg/50mcg(60D) Seretide 125_Evohaler 125mcg/25mcg(120D) Seretide 100_Accuhaler 100mcg/50mcg(60D) Fostair_Inh 100mcg/6mcg (120D) CFF £0.00 £10.00 £20.00 £30.00 £40.00 £50.00 £60.00 £70.00 £80.00 £90.00 Inhaler Use • With the correct technique, only 1/3 of the drug reaches the lungs, • What happens if inhaler is used incorrectly? • NICE : – recognises inhaler technique is often neglected – recommends it should be regularly reassessed and retaught • Where more than 1 type of inhalers is used, further problems can occur – studies have found an association with increased errors in the use of inhalers when different types of inhalers were used Healthcare professionals have sufficient knowledge of inhaler technique? • 150 Healthcare professionals (from 74 PCTs and 76 Acute Trusts) asked to demonstrate how to administer a pMDI • Included hospital doctors, hospital nurses, GPs, practice nurses, hospital and community pharmacy staff • Of 150 HCPs assessed: • Only 7% could demonstrate all the recognised steps • 75% of HCPs said they were involved in the teaching of inhaler technique • 48% were prescribers or involved in prescribing • 63% had received some training on inhaler technique in the past of which 67% said took place > a year ago Ref: Thorax Dec 2010 Vol 65 Suppl 4 Requirements for an optimal device • Simple handling • Device should facilitate – optimal respiratory flow of drug when device is used – correct inhalation technique – patient to verify medication inhalation has been successful • Dosage and deposition of active ingredient in the lungs must be sufficiently high and reproducible • Dose counter – so they know how much is left • Require minimal maintenance itself • Be acceptable to the patient so they will use it Virchow JC, et al. Respir Med 2007;102:10–9 What do experts say about the importance of inhaler device selection? “When prescribing a new inhaler, or reviewing patients’ progress, inhaler technique should be demonstrated by the clinician, followed by the patient. Many people forget how to use their inhaler devices, and this is likely to affect clinical outcomes” “The least cost effective inhaler device is the one that patients cannot use. In deciding which device and drug formulation to prescribe determine the patients ability to use the prescribed device correctly” General Practice Airways Group (GPIAG) Opinion Sheet on Inhaler Devices No.20; 2008 BTS recommends the “THREE CHECKS” • Before initiating or adjusting a new therapy, practitioners should always re-check: – 1. Adherence with existing therapy – 2. Inhaler technique – 3. Eliminate trigger factors BTS recommends: 1. Prescribe inhalers only after patients have received training in the use of the device by a competent healthcare professional and have demonstrated satisfactory technique 2. Reassess technique as part of the clinical review